Form 4: Janux Therapeutics CEO David Campbell Sells Shares Under 10b5-1 Trading Plan

Janux Therapeutics' CEO, David Alan Campbell, executed multiple sales of common stock on September 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 27, 2024, David Alan Campbell, the President and CEO of Janux Therapeutics, sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on June 21, 2024.
• Three separate transactions occurred with weighted average sale prices of $46.0893, $46.855, and $47.8384.
• The number of shares sold in each transaction were 18,957, 5,248, and 795 respectively.
• Following these transactions, Campbell directly owns 307,054 shares of Janux Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock sales by an executive. The sales were conducted under a pre-arranged plan, so it's neutral in sentiment.

Industry Context

Sales by company executives are a normal part of corporate governance. Investors often monitor these sales for insight into management's perspective on the company's valuation and future prospects. Sales under 10b5-1 plans are less likely to be indicative of management sentiment, as these plans are pre-arranged.

Stakeholder Impact

• The stock sales may have a minor impact on shareholders, potentially creating downward pressure on the stock price in the short term.

Key Dates